CD127-directed immunotherapy outperforms Imatinib in preclinical ABL-class fusion+ BCP-ALL via a dual mode of action

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

D. Pinkle - , Kiel University (Author)
A. Dietterle - , Kiel University (Author)
M. Cornils - , Kiel University (Author)
A. Laqua - , Kiel University (Author)
J. Heymann - , Kiel University (Author)
P. Fanter - , Kiel University (Author)
M. Brueggemann - , Kiel University (Author)
G. Cario - , Kiel University (Author)
D. M. Schewe - , Department of Paediatrics, National Center for Tumor Diseases Dresden (Author)
L. Lenk - , Kiel University (Author)